CurrentPremera BluecrossPolicy 5.01.587

PHARMACY / MEDICAL POLICY - 5.01.587 Hereditary Angioedema

Defines medical necessity criteria, site-of-service review rules, age limits, laboratory and clinical diagnostic requirements, benefit management (pharmacy vs medical) and dosing/authorization constraints for HAE-specific drugs managed by Premera Bluecross. Applies to IV, SC, oral and injectable therapies and includes site-of-service exceptions and documentation/coding guidance.

Policy Summary

PayerPremera Bluecross

PolicyPHARMACY / MEDICAL POLICY - 5.01.587 Hereditary Angioedema

Policy CodePolicy 5.01.587

Change TypeAge indication updates; product additions; coding and site-of-service clarifications

Effective DateMar. 1, 2026

Next Review DateN/A

Key ActionOffice visit notes with relevant history/physical and applicable laboratory test results must be submitted to document that medical necessity criteria are met.

POLICY UPDATE CHANGES

Site of Service Medical Necessity criteria does not apply to Alaska fully-insured members per Alaska HB 226.

Medications listed are subject to the product's FDA dosage and administration prescribing information.

Updated Orladeyo (berotralstat) coverage criteria age requirement from ≥12 years to ≥2 years.

Removed requirement to try danazol/another androgen for adult males from Haegarda, Orladeyo, Takhzyro, and Cinryze.

Updated Berinert, Kalbitor, and Ruconest to require trial with generic icatibant or Sajazir.

Updated Takhzyro coverage from ≥12 years to ≥2 years.

No clinical policy statement changes identified in 2026 review.

Removed Sajazir (icatibant) as a preferred treatment for acute attacks of hereditary angioedema.

Clarified that the generic icatibant step therapy requirement applies to individuals aged 18 years or older who are not currently pregnant for Berinert, Firazyr, Kalbitor, and Ruconest.

Added coverage for Andembry (garadacimab-gxii) and Dawnzera (donidalorsen) for long-term prophylaxis and added HCPCS code J3590 for these products.

Added Ekterly (sebetralstat) for treatment of acute attacks and included it as a qualifying acute treatment drug within criteria for Cinryze, Haegarda, Orladeyo, and Takhzyro.

Updated Orladeyo (berotralstat) coverage criteria age requirement from aged 12 years or older to 2 years or older (03/01/26 annual review).

Clarified that Site of Service Medical Necessity criteria can apply to injection drugs.

Policy updated to indicate that Site of Service Medical Necessity criteria does not apply to Alaska fully-insured members per Alaska HB 226.

Clarified that medications listed are subject to the product's FDA dosing and administration and that non-formulary exceptions may be approved up to 12 months.

MultipleDrugs covered (listed)

8Key HCPCS J-codes listed

VariesMinimum age criteria varies by drug

Andembry/Dawnzera/EkterlyNewly covered products

2+Age indication change (Orladeyo)

Coverage Summary

This policy covers therapies for hereditary angioedema (HAE) across three treatment intents: acute (on‑demand) treatment, short‑term/procedural prophylaxis, and long‑term prophylaxis. Covered drug classes include C1‑esterase inhibitor (C1‑INH) replacement (plasma‑derived and recombinant), kallikrein inhibitors (monoclonal antibodies and small molecules), bradykinin receptor antagonists, and antisense oligonucleotides, plus newly approved agents from 2025–2026 (e.g., Andembry, Dawnzera, Ekterly).

The policy references the WAO/EAACI guideline recommendations for acute and prophylactic management and requires adherence to product FDA labeling for dosing and administration. The coverage stance is described as mixed with product‑specific medical necessity criteria, site‑of‑service review rules (which do not apply to Alaska fully‑insured members), and managed benefit design differences (pharmacy vs medical). Key recent additions and updates include coverage for Andembry (garadacimab‑gxii) and Dawnzera (donidalorsen) for long‑term prophylaxis, addition of Ekterly (sebetralstat) for acute treatment, and lowering the Orladeyo (berotralstat) minimum age from ≥12 to ≥2 years.

Policy-level key stats & thresholds (selected)

Drugs covered (listed)Multiple (C1-INH products, kallikrein inhibitors, bradykinin antagonists, antisense oligonucleotides, new agents Andembry, Dawnzera, Ekterly)

Key HCPCS J-codes listedJ0593, J0596, J0597, J0598, J0599, J1290, J1744, J3590

Newly covered productsAdded Andembry and Dawnzera for long-term prophylaxis; Ekterly for acute attacks

Age indication change (Orladeyo)Orladeyo age lowered to 2 years (was ≥12)

Step therapy restrictionGeneric icatibant step therapy required for adults (≥18 years) not pregnant prior to some branded acute therapies

%FVC threshold≤ 40%

Ekterly dosing max1,200 mg in any 24-hour period; 2,400 mg every 30 days

Ruconest limitDose limited to 150 mg per day

Takhzyro dose limitMaintenance dose limited to 300 mg every 2 weeks

Medical Necessity Criteria (grouped)

Site of Service Medical Necessity (general)

Site of Service Medical Necessity (general). Site of service criteria apply to medical benefit reviews only and do not apply to Alaska fully‑insured members (see General policy changes and application). For individuals aged 13 years and older we review the location where IV or injectable HAE drugs are administered.

Operator: all — ALL of the following must be met:

Hospital outpatient medically necessary when ONE of the following is met:

- Initial course of infusion or injection of a pharmacologic or biologic agent (first 90 days).

- Re‑initiation of an agent after discontinuation of therapy for 6 months or longer (does not include agents with standard dosing intervals of 6 months or longer).

Acute Treatment Preferences & Step Therapy Rules

Step Therapy

Generic icatibant step requirement for certain acute therapies (adults)

Generic icatibant step requirement for certain acute therapies (adults). For adults (aged ≥18 years) who are not pregnant, a trial of generic icatibant is required prior to coverage of the listed alternative acute treatments unless contraindicated or not clinically appropriate.

Affected products: Firazyr (icatibant acetate), Berinert (pdC1-INH), Kalbitor (ecallantide), Ruconest (recombinant C1-INH).
Age & pregnancy applicability: Applies to individuals aged ≥18 years and not pregnant.
Preference change note: Sajazir removed from preferred product list in acute treatment pathway.
Exception: If generic icatibant is medically contraindicated (e.g., documented severe allergy) or not available in a timely manner, alternative therapies may be considered with documentation.

Documentation Required

Coding (HCPCS / J-codes)

HCPCS / J-codes for HAE drugsHCPCS

J0593	Injection, lanadelumab-flyo (Takhzyro), 1 mg
J0596	Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units
J0597	Injection, C-1 esterase inhibitor (human), Berinert, 10 units
J0598	Injection, C-1 esterase inhibitor (human), Cinryze, 10 units
J0599	Injection, c-1 esterase inhibitor (human), (Haegarda), 10 units
J1290	Injection, ecallantide (Kalbitor), 1 mg
J1744	Injection, icatibant, 1 mg (Firazyr, Sajazir, generic icatibant)
J3590	Unclassified biologics (use to report: Andembry and Dawnzera)

HCPCS codes added/updated (policy history)HCPCS

J0593	HCPCS code added (new code effective 10/1/19)
J0596	Previously added code
J0597	Previously added code
J0598	Previously added code
J0599	Added 02/01/19
J1290	Previously added code
J1744	Previously added code
J3490	Removed 08/01/19
J3590	Added for Andembry and Dawnzera (03/01/26)

Billing Rule

HCPCS code reporting for Andembry and Dawnzera

Andembry (garadacimab-gxii) and Dawnzera (donidalorsen) should be reported using HCPCS code J3590 (unclassified biologics) per the policy update; include the specific HCPCS code for other HAE products when billing.

Andembry and Dawnzera: J3590
Other common HAE codes: J0593, J0596, J0597, J0598, J0599, J1290, J1744

Management, Authorization & Reauthorization

Prior Authorization

Non-formulary exception duration

Non‑formulary exception reviews for drugs listed in this policy may be approved for periods up to 12 months. Providers should request an exception review when a non‑formulary drug is needed for a patient.

Approvals for non‑formulary exceptions may be granted up to 12 months
Providers should submit requests for exception review when non‑formulary drugs are required

Documentation Required

Follow FDA labeling

Prescribers must follow the product's FDA dosing and administration prescribing information for drugs in this policy; coverage is contingent on adherence to the product labeling.

Background & Evidence

Covered HAE therapy classes include C1‑INH replacement (Berinert, Cinryze, Haegarda, Ruconest), kallikrein inhibitors (lanadelumab/Takhzyro, berotralstat/Orladeyo, sebetralstat/Ekterly), bradykinin receptor antagonists (icatibant products: Firazyr, generic, Sajazir), and antisense oligonucleotides (Dawnzera). The policy also incorporates newer 2025 approvals including Andembry (FXIIa inhibitor) and Dawnzera, and the 2025 oral acute agent Ekterly.

The policy differentiates treatment intent: acute/on‑demand therapies (e.g., Berinert, Firazyr/generic icatibant, Kalbitor, Ruconest, Ekterly) for immediate attack management; short‑term/procedural prophylaxis (typically IV pdC1‑INH before procedures); and long‑term prophylaxis (e.g., Cinryze, Haegarda, Takhzyro, Orladeyo, Andembry, Dawnzera). It cites the WAO/EAACI guideline endorsing C1‑INH, lanadelumab, and berotralstat for first‑line long‑term prophylaxis and recommends C1‑INH, ecallantide, or icatibant for acute attacks. Product labeling and FDA‑approved age indications drive specific age limits and dosing requirements; management (pharmacy vs medical benefit) varies by product.

Evidence presented includes the phase 3 HELP trial for lanadelumab: a randomized, double‑blind, placebo‑controlled study (n=125) in individuals ≥12 years with baseline ≥1 attack/month comparing lanadelumab 150 mg Q4W, 300 mg Q4W, 300 mg Q2W, and placebo over 26 weeks. All lanadelumab regimens produced a significant reduction in mean monthly attack rate versus placebo (P<0.001), with the 300 mg SC every 2 weeks arm showing the numerically best results.

Safety data from HELP and supporting studies showed generally mild to moderate adverse events (injection‑site pain, erythema, headache) with no SAEs, deaths, or discontinuations due to AEs reported in the trial populations evaluated. The policy also references WAO/EAACI guideline recommendations as contextual evidence for treatment selection.

Revision History

03/01/2026revisedLatest

Updated Orladeyo (berotralstat) coverage criteria age requirement from ≥12 years to ≥2 years (03/01/26 annual review).

2026 (annual review noted Feb 9, 2026)administrative

2026 review found no other clinical policy statement changes beyond the Orladeyo age change.

10/01/2025 (policy history entries in 2025)added

Added coverage for Andembry (garadacimab-gxii) and Dawnzera (donidalorsen) for long-term prophylaxis and added HCPCS code J3590 for these products.

Policy Summary

PayerPremera Bluecross

PolicyPHARMACY / MEDICAL POLICY - 5.01.587 Hereditary Angioedema

Policy CodePolicy 5.01.587

Change TypeAge indication updates; product additions; coding and site-of-service clarifications

Effective DateMar. 1, 2026

Next Review DateN/A

Key ActionOffice visit notes with relevant history/physical and applicable laboratory test results must be submitted to document that medical necessity criteria are met.

On This Page

- No outpatient infusion center within 50 miles of the individual’s home and no contracted home infusion agency will travel to the home, or hospital is the only place that offers infusions/injections of this drug.

- Clinical condition that increases risk of complications for infusion/injection, including any ONE of: known symptomatic cardiac arrhythmia or significant respiratory disease (eg, serious obstructive airway disease, FVC ≤ 40%), unstable renal function decreasing ability to respond to fluids, difficult or unstable vascular access, acute mental status changes or cognitive impairment impacting safety of infusion/injection, known history of severe adverse drug reactions and/or anaphylaxis to related/similar drug.

Drug‑specific medical necessity for long‑term prophylaxis

Drug‑specific medical necessity for long‑term prophylaxis. ALL of the following must be met for coverage of specified prophylactic agents.

Operator: all — ALL of the following must be met:

Age and diagnosis:

- Individuals meet age requirement per product labeling (e.g., Cinryze: age ≥ 6 years; Andembry/Dawnzera: age ≥ 12 years).

Diagnostic laboratory criteria for HAE type I or II:

- Type I HAE established by ALL of: low C4; low C1‑INH antigenic (protein) level.

- Type II HAE established by ALL of: low C4; normal or high C1‑INH antigenic level; low C1‑INH functional level.

Clinical features: has ≥ 2 of the following: recurrent angioedema without wheals/urticaria; recurrent abdominal attacks; positive family history; failure to respond to antihistamines, glucocorticoids, or epinephrine.

Severity/need: ONE of the following: history of ≥1 HAE attacks per month over a 6‑month period requiring acute treatment with specified on‑label acute therapies (Berinert, Ekterly, Firazyr, generic icatibant, Kalbitor, Ruconest, Sajazir) OR documentation of pregnancy OR documentation of laryngeal HAE attack within the last 5 years.

Concomitant therapy: Treatment is not used concomitantly with other targeted HAE‑specific therapies for prophylactic treatment.

Product dosing limits / notes: Maintenance dose must comply with product‑specific limits (example: for certain agents maintenance dose limited to 200 mg once — see product labeling).

Long‑term prophylaxis coverage updates: recent policy updates expand covered prophylaxis options per FDA labeling and product approvals; ensure documented diagnostic labs and clinical criteria as above, and apply product‑specific age and dosing limits when authorizing long‑term prophylaxis. Authorization duration follows Management & authorization limits.

Drug‑specific medical necessity for acute treatment

Drug‑specific medical necessity for acute treatment. ALL of the following must be met unless otherwise specified by product labeling.

Operator: all — ALL of the following must be met:

Age and diagnosis: meet age requirement per product (product specific — e.g., Berinert for adults and pediatrics per labeling; Ekterly and some agents age ≥ 12 years).

Diagnostic branches (any of the following as applicable):

- Type I HAE: low C4 AND low C1‑INH antigenic level.

- Type II HAE: low C4 AND normal/high C1‑INH antigenic level AND low C1‑INH functional level.

- Acquired angioedema (where applicable per product): appropriate low C1q, low C4, low C1‑INH antigenic and functional levels as required by labeling (eg, for Ekterly).

Clinical features consistent with acute HAE attack (eg, angioedema without urticaria, progressive airway involvement, severe abdominal attacks).

Concomitant therapy exclusion: acute therapy is not used concomitantly with other targeted HAE‑specific therapies for acute treatment unless clinically justified and supported by documentation.

Dosing limits: dosing and frequency must follow product‑specific maximums per FDA labeling and policy dosing notes.

Additional acute criteria for some products:

- Generic icatibant pathway: policies may require a step to icatibant or define interchangeability and substitution rules; follow product‑specific step notes where applicable.

- Berinert/Kalbitor/Ruconest (and other C1‑INH or kallikrein inhibitors): follow age indications, weight‑based dosing, and re‑dosing limits per labeling; verify that claimed doses and intervals are within labeled acute treatment parameters.

- For agents with oral acute indications (eg, Ekterly): ensure diagnostic criteria include acquired HAE when required, and dose limits per labeling are applied.

Management & authorization limits

Management & authorization limits. Length of approval and reauthorization conditions for HAE therapies.

Operator: all — ALL of the following must be met:

Initial authorization duration: up to 12 months for indicated agents when initial criteria are met.

Reauthorization requirements: documentation of ongoing clinical benefit or continued need (eg, reduction in attack frequency for prophylaxis, documented appropriate use for acute attacks), adherence to product dosing limits, and absence of contraindicated concomitant targeted HAE therapies.

Non‑formulary exception: a non‑formulary exception may be granted for up to 12 months when criteria are met and clinical justification is provided.

Other authorization notes: apply product‑specific authorization windows and any special medical‑benefit site‑of‑service requirements (see Site of Service Medical Necessity).

General policy changes and application

General policy changes and application. High‑level policy statements and scope for application of this policy.

Operator: all — ALL of the following apply:

FDA labeling: Coverage and authorization decisions follow FDA‑approved indications, age limits, and dosing unless otherwise stated in this policy or supported by clinical justification.

Non‑formulary exception: Non‑formulary coverage may be approved per the Non‑Formulary Exception criteria for up to 12 months with documentation of medical necessity.

SOS exemption for Alaska: The Site of Service Medical Necessity criteria within this policy does NOT apply to Alaska fully‑insured members; for those members, refer to the infusion and injection drug Medical Necessity criteria only.

CRS exception: Hospital‑based outpatient setting is required for infusion/injection when cytokine release syndrome (CRS) is present and ALL of the following are met: CRS grade 3 or 4 evidenced by temperature ≥ 38°C, hypotension requiring ≥1 vasopressor, and hypoxia requiring high‑flow oxygen device or positive pressure ventilation; AND the individual will be admitted to an inpatient setting as soon as possible.

SOS applies to injections: Site of service review applies to both IV infusions and injectable therapies (including subcutaneous and intramuscular routes) for members age ≥13 as specified.

Application: This policy applies to medical benefit reviews; infusion/injection drugs managed under the pharmacy benefit are subject to drug‑specific medical necessity criteria in this document as indicated.

Submit medical records documenting criteria / Follow FDA labeling

Submit medical records documenting criteria. Coverage for acute HAE therapies is contingent on provision of required clinical documentation and adherence to FDA dosing and labeling where applicable.

Required records: office visit notes documenting the acute attack, relevant physical exam findings, and clinical indication for acute therapy.
Required records: laboratory results supporting HAE diagnosis when applicable (C4, C1-INH antigenic and functional levels, C1q if indicated).
Required records: prior treatment history including prior use/trial of generic icatibant for adults when step therapy is applicable, and documentation of contraindications if step not followed.
Coverage note: Coverage is contingent on adherence to FDA-approved dosing, administration route, and any labeled limitations; provide dosing details in the medical record.
Billing/coding note: Use the appropriate HCPCS J-code for the drug administered when billing the medical benefit (e.g., J-codes specific to each product per current coding guidance).

Prior Authorization

Site-of-service prior authorization for medical benefit IV/ injectable drugs

Site-of-service prior authorization for medical benefit IV/injectable drugs. For individuals aged ≥13 years, site-of-service (SOS) medical necessity review will be applied when the drug is managed under the medical benefit. Alaska fully insured members are exempt from SOS review per HB 226; refer to infusion and injection drug Medical Necessity criteria only for Alaska fully-insured members.

SOS review applies for ages ≥13 for IV/injectable drugs managed under the medical benefit; review determines the most appropriate, safe, and cost-effective site (office, infusion center, home, outpatient hospital).
Alaska exemption: The Site of Service Medical Necessity criteria within this policy DOES NOT apply to Alaska fully-insured members per HB 226 — use infusion/injection drug criteria only.
When prior authorization may be required: Prior authorization may be required to approve a non-preferred site (e.g., outpatient hospital) beyond initial allowable criteria (first 90 days or re-initiation after ≥6 months), or when clinical risk factors (cardiac/pulmonary instability, unstable vascular access, severe adverse reaction history) justify a higher acuity site.
Billing/coding reminder: Use the appropriate HCPCS J-code for the drug administered when requesting SOS review/PA.

Coverage contingent on adherence to FDA dosing and administration information

Follow the specific product labeling for dosing and administration

LowBelow the lower limit of normal as defined by the laboratory test.

Site of Service (SOS)Location where the drug is administered (hospital-based outpatient, infusion center, physician's office, or home); SOS medical necessity reviewed for individuals aged ≥13 (does not apply to Alaska fully‑insured members).

10/01/2025 (policy history entries in 2025)added

Added Ekterly (sebetralstat) for treatment of acute attacks and included Ekterly as a qualifying acute treatment drug within criteria for Cinryze, Haegarda, Orladeyo, and Takhzyro.

07/01/2025 (effective Oct 3, 2025 provider notification noted)clarified

Policy updated to indicate Site of Service (SOS) Medical Necessity criteria does not apply to Alaska fully-insured members pursuant to Alaska HB 226 (accessed January 3, 2025).

07/01/2025clarified

Clarified that the generic icatibant step therapy requirement applies to individuals aged 18 years or older who are not currently pregnant for Berinert, Firazyr, Kalbitor, and Ruconest.

09/01/2024 (effective Dec 5, 2024 per history)revised

Removed requirement to try danazol/another androgen for adult males from Haegarda, Orladeyo, Takhzyro, and Cinryze.

09/01/2024 (effective Dec 5, 2024 per history)revised

Updated Berinert, Kalbitor, and Ruconest to require trial with generic icatibant or Sajazir.

2024 (policy text and history indicate updates)removed

Removed Sajazir (icatibant) as a preferred treatment for acute attacks of hereditary angioedema (removed from preferred listings in 2025 entries and history).